001367 Zhejiang Haisen Pharmaceutical
- 38.28
- -0.52-1.34%
Zhejiang Haisen Pharmaceutical News
Heisen Pharmaceuticals (001367.SZ) equity distribution for 2023: For every 10 shares, 4.8 shares will be converted and 5 yuan will be distributed.
Haisen Pharmaceutical (001367.SZ) announced that the company's annual equity distribution plan for 2023 is to distribute dividends in cash at a rate of 8.5 yuan (tax included) per 10 shares to all shareholders by 28 May 2024 based on the total number of existing shares at the end of the ex-dividend day, and no bonus shares will be issued.
Hisense Pharmaceutical (001367.SZ): The company has products involving the use of biosynthesis related technologies such as enzymatic catalytic reactions
Gelonghui, May 7 | Hisense Pharmaceutical (001367.SZ) said on the investor interactive platform that the company has products involving the use of biosynthesis-related technologies such as enzymatic catalytic reactions. This technology has the advantages of high stereoselectivity, mild reaction conditions, good environmental protection, and low comprehensive cost. In order to further enhance the wide application of related technologies in production, the company cooperated with the Jinhua Research Institute of Zhejiang University and others, and related research work is being actively promoted.
Zhejiang Haisen Pharmaceutical's (SZSE:001367) Profits Appear To Have Quality Issues
Zhejiang Haisen Pharmaceutical Co., Ltd. (SZSE:001367) just released a solid earnings report, and the stock displayed some strength. Despite this, our analysis suggests that there are some factors we
Hisense Pharmaceutical (001367.SZ): Net profit of 33.3848 million yuan in the first quarter increased 33.55% year-on-year
Gelonghui, April 24 | Hisense Pharmaceutical (001367.SZ) released its report for the first quarter of 2024, with operating income of 116 million yuan, up 8.27% year on year; net profit attributable to shareholders of listed companies was 33.3848 million yuan, up 33.55% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 32.641 million yuan, up 30.49% year on year; basic earnings per share were 0.49 yuan.
Hisense Pharmaceutical (001367.SZ): Net profit of 105 million yuan in 2023, plans to convert 10 to 4.8 to 5 yuan
Gelonghui, April 22丨Hysen Pharmaceutical (001367.SZ) announced its 2023 annual report. Operating income for the reporting period was 397 million yuan, down 5.99% year on year; net profit attributable to shareholders of listed companies was 105 million yuan, down 2.72% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 101 million yuan, down 0.14% year on year; basic income per share was 1.68 yuan; it plans to distribute a cash dividend of 5 yuan (tax included) for every 10 shares to all shareholders.
Zhitong A Share Sale Restriction and Release List | April 10
According to the Zhitong Finance App, the ban on restricted shares of 12 listed companies was lifted on April 10, with a total market value of about 10.058 billion yuan. Today's specific sales restrictions and unbanned shares are as follows: Stock abbreviation, stock code, restricted stock type, number of banned shares, Dengkang Dental 001328, pre-issuance of 2.9877 million shares, palm shares, 002431, original shareholder placement of 326 million additional A shares, original shareholder placement listing 7059,000, Shaanxi Energy 001286 shares limited sale and circulation of 300 million yuan, China Power Port 001287 shares limited sale and circulation of 247 million before issuance
Should Weakness in Zhejiang Haisen Pharmaceutical Co., Ltd.'s (SZSE:001367) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
With its stock down 15% over the past week, it is easy to disregard Zhejiang Haisen Pharmaceutical (SZSE:001367). However, stock prices are usually driven by a company's financials over the long ter
Declining Stock and Decent Financials: Is The Market Wrong About Zhejiang Haisen Pharmaceutical Co., Ltd. (SZSE:001367)?
Zhejiang Haisen Pharmaceutical (SZSE:001367) has had a rough three months with its share price down 16%. However, stock prices are usually driven by a company's financials over the long term, which
Heisen Pharmaceutical (001367.SZ): Currently, the company does not produce azithromycin
Glonghui, Oct. 23 | An investor asked Heisen Pharmaceutical (001367.SZ) on the investor interactive platform, “Does the company produce azithromycin?” The company replied that the company currently has a product system that mainly uses digestive, antipyretic, analgesic, and cardiovascular APIs, complemented by APIs such as antidepressants and antimicrobials, and is also prepared with special APIs and preparations such as antiviral and non-steroidal anti-inflammatory drugs. Currently, the company does not produce azithromycin.
Hisen Pharmaceutical (001367.SZ) will list 341,600 restricted shares for circulation on October 17
Hisen Pharmaceutical (001367.SZ) announced that the number of shareholders whose share sales restrictions have been lifted this time is 7,711. The explanation...
Heisen Pharmaceutical (001367.SZ): The main products currently under development include APIs and pharmaceutical products
Glonghui, Oct. 10丨Hyssen Pharmaceutical (001367.SZ) said on the investor interactive platform that the main products currently being developed by the company include APIs and pharmaceutical products.
Haisen Pharmaceutical to Invest 3 Billion Yuan on New Factory
Zhejiang Haisen Pharmaceutical (SHE:001367) has earmarked 3 billion yuan on a new factory within the Zhejiang Dongyang Economic Development Zone. The Chinese pharmaceutical ingredients and intermediat
Hisen Pharmaceutical (001367.SZ) signed a letter of intent to invest in a new plant construction project in Dongyang Economic Development Zone
Hisen Pharmaceutical (001367.SZ) issued an announcement. According to relevant documents of the Dongyang Municipal Government, in an effort to promote Zhejiang Hisen...
Hayson Pharmaceutical (001367.SZ): The antidepressant being developed is a paroxetine hydrochloride preparation
GLONGHUI, September 6丨Hyssen Pharmaceutical (001367.SZ) held a performance briefing on September 6, 2023, on “What is the current status of antidepressant drugs developed by the company?” The company replied that the antidepressant products that the company has already listed include escitalopram oxalopram and its formulation, and paroxetine hydrochloride raw material; the antidepressant currently being developed is paroxetine hydrochloride preparation.
Hayson Pharmaceutical (001367.SZ): Not involved in the production and operation of diet pills
Glonghui September 6th 丨 Hyssen Pharmaceutical (001367.SZ) held a performance briefing on September 6, 2023, on “Is the company involved in weight loss drugs?” The company replied that the company was not involved in the production and operation of diet pills during the reporting period.
Hayson Pharmaceutical (001367.SZ): The company is developing a total of 14 products, including 4 pharmaceutical products
Glonghui September 6th 丨 Hyssen Pharmaceutical (001367.SZ) held a performance briefing on September 6, 2023, on “Has the company developed new varieties of formulations?” The company replied that during the reporting period, the company was developing a total of 14 products, including 4 formulation products.
Hyson Pharmaceutical (001367.SZ): Net profit fell 19.45% in the first half of the year to 458.077 million yuan
Glonghui, August 22丨Hyson Pharmaceutical (001367.SZ) announced its 2023 semi-annual report. Operating revenue for the reporting period was 193 million yuan, down 8.50% year on year; net profit attributable to shareholders of listed companies was 458.077 million yuan, down 19.45% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 444,543 million yuan, down 13.96% year on year; basic earnings per share were 0.81 yuan.
Haisen Pharmaceutical Surges 77% in Shenzhen Listing Debut
10:21 PM EDT, 04/09/2023 (MT Newswires) -- Zhejiang Haisen Pharmaceutical (SHE:001367) surged 77% when it debuted on the Shenzhen Stock Exchange's main board Monday morning. Shares of the Chinese prod
Haisen Pharmaceutical to Raise 756 Million Yuan From Shenzhen IPO
06:48 AM EDT, 03/27/2023 (MT Newswires) -- Zhejiang Haisen Pharmaceutical (SHE:001367) is looking to raise 756.2 million yuan from its initial public offering on the Shenzhen Stock Exchange's main boa
Haisen Pharmaceutical Secures Approval to Launch Shenzhen IPO
10:34 PM EDT, 03/20/2023 (MT Newswires) -- Zhejiang Haisen Pharmaceutical (SHE:001367) received the green light from the China Securities Regulatory Commission to launch its initial public offering on
Analysis
Price Target
No Data
